venetoclax (Rx)

Brand and Other Names:Venclexta
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 10mg
  • 50mg
  • 100mg

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Indicated for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Dose ramp-up phase

  • Administer dose according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg
  • Ramp-up dosing schedule designed to gradually reduce tumor burden and decrease risk of tumor lysis syndrome
  • Week 1: 20 mg PO qDay
  • Week 2: 50 mg PO qDay
  • Week 3: 100 mg PO qDay
  • Week 4: 200 mg PO qDay
  • Week 5 and beyond: 400 mg PO qDay

Monotherapy

  • 400 mg PO qDay after completing the weekly ramp-up dosing
  • Continue until disease progression or unacceptable toxicity

Combination with obinutuzumab

  • Cycle 1
    • Day 1: Obinutuzumab 100 mg IV
    • Day 2: Obinutuzumab 900 mg IV
    • Days 8 and 15: Obinutuzumab 1000 mg IV
    • Day 22: Start venetoclax according to 5-week ramp up schedule
  • Cycle 2
    • Day 1: Obinutuzumab 1000 mg IV
    • Day 28: After completing the ramp-up phase on Cycle 2 Day 28, continue venetoclax 400 mg qDay from Cycle 3 Day 1 until Cycle 12 Day 28
  • Cycles 3-6
    • Day 1: Obinutuzumab 1000 mg IV
    • Days 1-28: Continue venetoclax 400 mg PO qDay
  • Cycles 7-12
    • Days 1-28: Continue venetoclax 400 mg PO qDay

Combination with rituximab

  • Venetoclax
    • Complete 5-week ramp-up dosing to reach 400 mg PO qDay
    • Continue venetoclax 400 mg PO qDay for 24 months from Cycle 1 Day 1 of rituximab
  • Rituximab
    • Initiate 375 mg/m² IV after patient has received venetoclax 400 mg/day x 7 days (ie, this will be Day 1 of Cycle 1)
    • 500 mg/m² IV on Day 1 for Cycles 2-6

Acute Myeloid Leukemia

In combination with azacitidine or decitabine or low-dose cytarabine for treatment in adults (≥75 years) who are newly-diagnosed acute myeloid leukemia (AML) or who have comorbidities that preclude use of intensive induction chemotherapy

Venetoclax dosing depends on the combination agent

Dose ramp-up phase

  • Day 1: 100 mg PO qDay
  • Day 2: 200 mg PO qDay
  • Day 3: 400 mg PO qDay
  • Day 4 and beyond (in combination with decitabine or azacitidine): 400 mg PO qDay
  • Day 4 and beyond (in combination with low-dose cytarabine): 600 mg PO qDay
  • In combination with decitabine, azacitidine, or low-dose cytarabine: Continue until disease progression or unacceptable toxicity

Dosage Modifications

For a dosing interruption >1 week during the first 5 weeks of ramp-up phase or >2 weeks after completing the ramp-up phase, reassess for risk of tumor lysis syndrome (TLS) to determine if reinitiation with a reduced dose is necessary (eg, all or some levels of the dose ramp-up schedule)

Consider discontinuing treatment for patients who require dose reductions to <100 mg for >2 weeks

Dose reduction schedule (CLL/SLL)

  • Dose at interruption 400 mg: Restart at 300 mg
  • Dose at interruption 300 mg: Restart at 200 mg
  • Dose at interruption 200 mg: Restart at 100 mg
  • Dose at interruption 100 mg: Restart at 50 mg
  • Dose at interruption 50 mg: Restart at 20 mg
  • Dose at interruption 20 mg: Restart at 10 mg
  • During the ramp-up phase, continue reduced dose for 1 week before increasing the dose

Tumor lysis syndrome

  • Modify for any occurrence of blood chemistry changes or symptoms suggestive of TLS
  • Withhold the next day’s dose; if resolved within 24-48 hr of last dose, resume at the same dose
  • For any blood chemistry changes requiring >48 hr to resolve, resume at a reduced dose
  • For any events of clinical TLS, resume at a reduced dose following resolution

Grade 3 or 4 nonhematologic toxicities

  • First occurrence: Interrupt dose; once resolved to grade ≤1, resume at same dose; no dose modification is required
  • Second and subsequent occurrences: Interrupt dose; follow dose reduction schedule when resuming treatment after resolution; a larger dose reduction may be used at discretion of physician

Hematologic toxicities (CLL/SLL)

  • Grade 3 or 4 neutropenia with infection or fever, or grade 4 hematologic toxicities (except lymphopenia)
  • First occurrence: Interrupt dose; reduce infection risks with neutropenia by administering G-CSF with venetoclax if clinically indicated; once toxicity resolves to grade ≤1, resume at the same dose
  • Second and subsequent occurrences: Interrupt dose; consider using G-CSF as clinically indicated; follow dose reduction schedule when resuming treatment after resolution; a larger dose reduction may be used at discretion of physician

Hematologic toxicities (AML)

  • Grade 4 neutropenia with or without fever or infection; or Grade 4 thrombocytopenia
  • Occurrence prior to achieving remission: Transfuse blood products, administer prophylactic and treatment anti-infectives as clinically indicated
  • First occurrence after remission (last ≥7 days): Delay subsequent treatment cycle of venetoclax and azacitidine, decitabine, or low-dose cytarabine; monitor blood counts; once resolved to Grade 1 or 2, resume all therapy at same dose
  • Subsequent occurrence after remission (last ≥7 days): Delay subsequent treatment cycle of venetoclax and azacitidine, decitabine, or low-dose cytarabine; monitor blood counts; once resolved to Grade 1 or 2, resume all therapy at same dose and reduce duration by 7 days for each subsequent cycle

Coadministration with strong CYP3A4 inhibitors

  • CLL/SLL
    • Dose ramp-up phase: Contraindicated
    • After ramp-up phase, consider alternative medications or reduce dose to 70 mg (coadministered with posaconazole) and 100 mg (coadministered with other strong CYP3A4 inhibitors)
  • AML
    • Day 1: Reduce to 10 mg
    • Day 2: Reduce to 20 mg
    • Day 3: Reduce to 50 mg
    • Day 4: Reduce to 70 mg (coadministered with posaconazole) OR 100 mg (coadministered with other strong CYP3A4 inhibitors
    • Steady daily dose (after ramp-up phase): Reduce dose to 70 mg (coadministered with posaconazole) and 100 mg (coadministered with other strong CYP3A4 inhibitors)
    • Resume venetoclax dose used prior to initiating the CYP3A inhibitor or P-gp inhibitor 2-3 days after discontinuation of inhibitor

Coadministration with moderate CYP3A inhibitor or P-gp inhibitor

  • Reduce venetoclax dose by at least 50%
  • Resume venetoclax dose used prior to initiating the CYP3A inhibitor or P-gp inhibitor 2-3 days after discontinuation of the inhibitor

Renal impairment

  • Mild or moderate (CrCl ≥30 mL/min): No dosage adjustment necessary
  • Severe (CrCl <30 mL/min) or patients on dialysis: Recommended dose has not been determined

Hepatic impairment

  • Mild or moderate (Child-Pugh A or B): No dosage adjustment; closely monitor for signs of toxicity during initiation and ramp-up phases
  • Severe (Child-Pugh C): Reduce venetoclax dose by 50%; monitor

Dosing Considerations

Patients without 17p deletion at diagnosis should be retested at relapse because acquisition of 17p deletion can occur

TLS risk

  • Assess patient-specific factors for level of risk of TLS and provide prophylactic hydration and antihyperuricemics prior to first dose to reduce risk of TLS
  • Perform tumor burden assessments, including radiographic evaluation (eg, CT scan)
  • Assess blood chemistry (potassium, uric acid, phosphorus, calcium, and creatinine) in all patients and correct preexisting abnormalities prior to initiation; monitor blood chemistries for TLS
  • AML
    • All patients should have WBC<25 x 10^9/L prior to initiation
    • Consider reducing venetoclax starting dose and closely monitor patients with risk factors for TLS (eg, circulating blasts, high burden of leukemia involvement in bone marrow, elevated pretreatment LDH levels, reduced renal function

TLS prophylaxis (CLL/SLL)

  • Low tumor burden (all lymph nodes (LNs) <5 cm AND absolute lymphocyte count (ALC) <25 x10^9/L)
    • Hydration: Oral (1.5-2 L)
    • Give allopurinol or xanthine oxidase inhibitor 2-3 days prior to initiation
    • Administer IV hydration for patients unable to tolerate oral hydration
    • Outpatient monitoring (20-mg or 50-mg dose): Blood chemistry predose, at 6-8 hr, and 24 hr after first dose and predose for subsequent ramp-up doses
  • Medium tumor burden (any LN 5 to <10 cm OR ALC ≥25 x10^9/L)
    • Hydration: Oral (1.5-2 L, also consider additional IV hydration)
    • Give allopurinol or xanthine oxidase inhibitor (2-3 days prior to initiation)
    • Administer IV hydration for patients unable to tolerate oral hydration
    • Outpatient monitoring (20-mg or 50-mg dose): Blood chemistry predose, at 6-8 hr, and 24 hr after first dose and predose for subsequent ramp-up doses; consider hospitalization for patients with CrCl <80 mL/min at first dose
  • High tumor burden (any LN ≥10 cm OR, ALC ≥25 x10^9/L AND any LN ≥5 cm)
    • Hydration: Oral (1.5-2 L) and IV (150-200 mL/hr as tolerated)
    • Give allopurinol 2-3 days before initiating venetoclax; consider rasburicase if baseline uric acid is elevated
    • Inpatient monitoring (20-mg or 50-mg dose): Blood chemistry predose, 4, 8, 12, and 24 hr
    • Outpatient monitoring (subsequent ramp-up doses): Blood chemistry at predose, at 6-8 hr, and 24 hr after dose

Orphan Designations

Multiple myeloma

Mantle cell lymphoma

Sponsor

  • AbbVie Inc; 1 Waukegan Road, Dept PA77, Bldg. AP30; North Chicago, Illinois 60044

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and venetoclax

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            All grades of severity listed unless otherwise indicated

            >10% (Combination with rituximab)

            Leukopenia (89%)

            Lymphopenia (87%)

            Neutropenia (65-86%)

            Neutropenia, Grade 3 or 4 (62-64%)

            Hypocalcemia (62%)

            Hypophosphatemia (57%)

            Lymphopenia, Grade 3 or 4 (56%)

            Leukopenia, Grade 3 or 4 (46%)

            Diarrhea (43%)

            Increased AST/SGOT (46%)

            Diarrhea (40%)

            Upper respiratory tract infection (39%)

            Hyperuricemia (36%)

            Increased alkaline phosphatase (35%)

            Hyperbilirubinemia (33%)

            Hyponatremia (30%)

            Hypokalemia (29%)

            Hyperkalemia (24%)

            Hypernatremia (24%)

            Nausea (21%)

            Musculoskeletal pain (19%)

            Lower respiratory tract infection (18%)

            Anemia (16%)

            Thrombocytopenia (15%)

            Constipation (14%)

            Hypophosphatemia, Grade 3 or 4 (14%)

            Abdominal pain (13%)

            Rash (13%)

            Headache (11%)

            Insomnia (11%)

            >10% (Monotherapy)

            Neutropenia (50%)

            Neutropenia, Grade 3 or 4 (45%)

            Nausea (42%)

            Upper respiratory tract infection (36%)

            Anemia (33%)

            Fatigue (32%)

            Thrombocytopenia (29%)

            Edema (22%)

            Thrombocytopenia, Grade 3 or 4 (20%)

            Anemia, Grade 3 or 4 (18%)

            Abdominal pain (18%)

            Pyrexia (18%)

            Vomiting (16%)

            Constipation (16%)

            Mucositis (13%)

            Lymphopenia (11%)

            1-10% (Combination with rituximab)

            Mucositis (10%)

            Pneumonia (10%)

            Vomiting (8%)

            Lymphopenia, Grade 3 or 4 (7%)

            Hyponatremia, Grade 3 or 4 (6%)

            Hypokalemia, Grade 3 or 4 (6%)

            Hypocalcemia, Grade 3 or 4 (5%)

            Febrile neutropenia (4%)

            Hyperbilirubinemia, Grade 3 or 4 (4%)

            Diarrhea, Grade 3 or 4 (3%)

            TLS, Grade 3 or 4 (3%)

            Hyperkalemia, Grade 3 or 4 (3%)

            Upper respiratory tract infection, Grade 3 or 4 (2%)

            Lower respiratory tract infection, Grade 3 or 4 (2%)

            Increased AST/SGOT (2%)

            Hypernatremia, Grade 3 or 4 (1%)

            Musculoskeletal pain, Grade 3 or 4 (1%)

            Increased alkaline phosphatase, Grade 3 or 4 (1%)

            1-10% (Monotherapy)

            Febrile neutropenia (6%)

            Fatigue, Grade 3 or 4 (4%)

            Abdominal pain, Grade 3 or 4 (3%)

            Diarrhea, Grade 3 or 4 (3%)

            Edema, Grade 3 or 4 (2%)

            Nausea, Grade 3 or 4 (1%)

            Vomiting, Grade 3 or 4 (1%)

            Upper respiratory tract infection, Grade 3 or 4 (1%)

            <1%

            Monotherapy

            • Constipation, Grade 3 or 4
            • Mucositis, Grade 3 or 4
            • Pyrexia, Grade 3 or 4
            Previous
            Next:

            Warnings

            Contraindications

            Strong CYP3A inhibitors at initiation and during ramp-up phase

            Cautions

            TLS, including fatal events and renal failure requiring dialysis, has occurred in previously treated CLL patients with high tumor burden when treated with venetoclax

            Neutropenia frequently reported; monitor complete blood cllcounts throughout treatment period

            Fatal and serious infections such as pneumonia and sepsis have occurred; monitor patients closely for signs and symptoms of infection and treat promptly; withhold therapy for Grade 3 and higher infection

            Do not administer live attenuated vaccines prior to, during, or after treatment until B-cell recovery occurs; safety and efficacy of immunization with live attenuated vaccines during or following therapy have not been studied; advise patients that vaccinations may be less effective

            Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered to a pregnant woman

            In a randomized trial in patients with relapsed or refractory multiple myeloma, the addition of venetoclax to bortezomib plus dexamethasone, resulted in increased mortality; treatment of patients with multiple myeloma with venetoclax in combination with bortezomib plus dexamethasone is not recommended outside of controlled clinical trials

            Drug interaction overview

            • Effects of other drugs on venetoclax
              • Venetoclax is a CYP3A substrate
              • Concomitant use with a strong or moderate CYP3A inhibitor or a P-gp inhibitor increases venetoclax plasma concentrations and toxicities, including the risk of TLS
              • Avoid grapefruit products, Seville oranges, and starfruit during treatment, as they contain inhibitors of CYP3A
              • Concomitant use with a strong CYP3A inducer decreases venetoclax plasma concentrations and efficacy
            • Venetoclax effects on other drugs
              • Venetoclax has inhibition potential on P-gp substrates at therapeutic dose levels in the gut; therefore, avoid coadministration with narrow-therapeutic index P-gp substrates
              • Coadministration with warfarin increases warfarin peak plasma concentrations and AUC, which may increase the risk of bleeding; closely monitor INR
            Previous
            Next:

            Pregnancy

            Pregnancy

            There are no available human data on use in pregnant women; based on its mechanism of action and findings in animals, may cause embryofetal harm when administered to a pregnant woman

            Females of reproductive potential should undergo pregnancy testing before initiation

            Animal studies

            • In mice, venetoclax was fetotoxic at exposures 1.2 times the human clinical exposure based on AUC at the recommended human dose of 400 mg daily

            Fertility and contraception

            • Advise females of reproductive potential to use effective contraception during treatment and for at least 30 days after the last dose
            • Male fertility may be compromised by treatment

            Lactation

            Unknown if distributed in human breast milk; advise nursing women to discontinue breastfeeding during treatment

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Selective inhibitor of the B-cell lymphoma 2 (Bcl-2) regulator protein, an antiapoptotic protein

            Overexpression of Bcl-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutic agents

            Venetoclax helps restore the process of apoptosis by binding directly to the Bcl-2 protein, displacing proapoptotic proteins like BIM (a novel member of the Bcl-2 family), triggering mitochondrial outer membrane permeabilization, and activating caspases

            Absorption

            Peak plasma time: 5-8 hr

            Peak plasma concentration at steady-state: 2.1 mcg/mL (400 mcg/day)

            AUC at steady-state: 32.8 mcg·hr/mL (400 mcg//day)

            Food effects

            • Administration with a low-fat meal increased venetoclax exposure by ~3.4-fold and administration with a high-fat meal increased venetoclax exposure by 5.1- to 5.3-fold compared withto fasting conditions
            • Venetoclax should be administered with a meal

            Distribution

            Protein bound: >99.9%

            Vd: 256-321 L

            Metabolism

            Metabolized by CYP3A4/5

            M27 was identified as a major metabolite in plasma with an inhibitory activity against Bcl-2 that is at least 58-fold lower than venetoclax in vitro

            Elimination

            Half-life: 26 hr

            Excretion: >99.9% in feces; <0.1% in urine

            Previous
            Next:

            Administration

            Oral Administration

            Administer 1 time a day with a meal and water at about the same time each day

            Swallow whole; do not chew, crush, or break tablets

            Missed dose

            • If dose is missed within 8 hr of scheduled dose, take as soon as possible
            • If a patient misses a dose by >8 hr, skip dose and resume usual dosing schedule the next day
            • If patient vomits following dosing, do not take an extra dose; take the next prescribed dose at the usual time

            Storage

            Tablets: Store at ≥86°F (30°C); keep tablets in the original package during the first 4 weeks of treatment; do not transfer tablets to a different container

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.